Position in LLY
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$420,999
+$189,217 QoQ
Shares Held
351
+39.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.32%
of 13F equity value
Holder Rank
#3,893
of 4,605 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Kapstone Financial Advisors LLC holds $8,529,634 across 7 Drug Manufacturers - General names. LLY ranks #5 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
15,264 | $3,841,032 | |
| 2 | JNJ |
Johnson & Johnson
|
8,363 | $2,123,951 | |
| 3 | MRK |
Merck & Co., Inc.
|
8,968 | $1,152,388 | |
| 4 | NVS |
Novartis AG
|
2,695 | $422,360 | |
| 5 | LLY |
ELI LILLY & Co
This page
|
351 | $420,999 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,977 | $344,394 | |
| 7 | AZN |
Astrazeneca PLC
|
1,184 | $224,510 |
All Filings in LLY
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $420,999 | 351 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $231,782 | 252 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $270,819 | 252 | Shares | Sole | 2026-02-05 | |
| 2025-03-31 | $208,129 | 252 | Shares | Sole | 2025-04-11 | |
| 2024-12-31 | $194,544 | 252 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $678,630 | 766 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $461,743 | 510 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $361,751 | 465 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $271,057 | 465 | Shares | Sole | 2024-02-05 | |
| No filing history on record for this holder in this stock. | ||||||